Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer

Sung Chul Park; Hoon Jai Chun

doi:10.4166/kjg.2015.66.1.1

Journal List > Korean J Gastroenterol > v.66(1) > 1007404

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park and Chun: Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer

Editorial

Korean J Gastroenterol 2015;66(1):1-4.

Published online: 4 October 2015

DOI: https://doi.org/10.4166/kjg.2015.66.1.1

Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer

Sung Chul Park, Hoon Jai Chun¹

Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea

¹Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

Correspondence to: Hoon Jai Chun, Department of Internal Medicine, Korea University Anam Hospital, 73 Inchon-ro, Seongbuk-gu, Seoul 136-705, Korea. Tel: +82-2-920-6555, Fax: +82-2-953-1943, E-mail: drchunhj@chol.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer

References

1. Wagner AD, Unverzagt S, Grothe W, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2010; (3):CD004064.

2. Cunningham D, Starling N, Rao S, et al. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 2008; 358:36–46.

3. Kang YK, Kang WK, Shin DB, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009; 20:666–673.

4. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008; 9:215–221.

5. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687–697.

6. Thuss-Patience PC, Kretzschmar A, Bichev D, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer–a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011; 47:2306–2314.

7. Kang JH, Lee SI, Lim do H, et al. Salvage chemotherapy for pre-treated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012; 30:1513–1518.

8. Ford HE, Marshall A, Bridgewater JA, et al. COUGAR-02 Investigators. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an openlabel, phase 3 randomised controlled trial. Lancet Oncol. 2014; 15:78–86.

9. Hironaka S, Ueda S, Yasui H, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013; 31:4438–4444.

10. Fuchs CS, Tomasek J, Yong CJ, et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014; 383:31–39.

11. Wilke H, Muro K, Van Cutsem E, et al. RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gas-tro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014; 15:1224–1235.

12. Kwon HJ, Park MI, Park SJ, et al. Efficacy and safety of FOLFIRI after failure of FOLFOX-4 in advanced gastric cancer. Korean J Gastroenterol. 2015; 66:10–16.

13. Seo MD, Lee KW, Lim JH, et al. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Jpn J Clin Oncol. 2008; 38:589–595.

14. Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol. 2004; 15:64–69.

15. Kim SH, Lee GW, Go SI, et al. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol. 2010; 33:572–576.

16. Lorizzo K, Fazio N, Radice D, et al. Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer. Cancer Chemother Pharmacol. 2009; 64:301–306.

17. Kim ST, Kang WK, Kang JH, et al. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Br J Cancer. 2005; 92:1850–1854.

18. Jeon EK, Hong SH, Kim TH, et al. Modified FOLFIRI as second-line chemotherapy after failure of modified FOLFOX-4 in advanced gastric cancer. Cancer Res Treat. 2011; 43:148–153.

19. Ji SH, Lim do H, Yi SY, et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer. 2009; 9:110.

20. Park JS, Lim JY, Park SK, et al. Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer. Cancer Res Treat. 2011; 43:236–243.

21. Sencan O, Buyukcelik A, Yalcin B, et al. The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. Eur J Cancer Care (Engl). 2008; 17:26–32.

TOOLS

Similar articles